FS-120
- Generic Name
- FS-120
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- invoX Pharma Limited
- Target Recruit Count
- 82
- Registration Number
- NCT04648202
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath